000 01419 a2200409 4500
005 20250518041746.0
264 0 _c20210427
008 202104s 0 0 eng d
022 _a1592-8721
024 7 _a10.3324/haematol.2018.213314
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aHolthof, Lisa C
245 0 0 _aPreclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.
_h[electronic resource]
260 _bHaematologica
_c2020
300 _ae80-e83 p.
_bdigital
500 _aPublication Type: Letter; Research Support, Non-U.S. Gov't
650 0 4 _aBenzodioxoles
650 0 4 _aHumans
650 0 4 _aIndolizines
650 0 4 _aMultiple Myeloma
_xdrug therapy
650 0 4 _aSurvivin
_xantagonists & inhibitors
700 1 _avan der Horst, Hilma J
700 1 _avan Hal-van Veen, Susan E
700 1 _aRuiter, Ruud W J
700 1 _aLi, Fengzhi
700 1 _aBuijze, Marijke
700 1 _aAndersen, Morten N
700 1 _aYuan, Huipin
700 1 _ade Bruijn, Joost
700 1 _avan de Donk, Niels W C J
700 1 _aLokhorst, Henk M
700 1 _aZweegman, Sonja
700 1 _aGroen, Richard W J
700 1 _aMutis, Tuna
773 0 _tHaematologica
_gvol. 105
_gno. 2
_gp. e80-e83
856 4 0 _uhttps://doi.org/10.3324/haematol.2018.213314
_zAvailable from publisher's website
999 _c29723914
_d29723914